OM
RARX

Opaleye Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Opaleye Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-141,800
Closed -$6.66M – 55
2019
Q4 		$6.66M Hold
141,800
– – 1.31% 34
2019
Q3 		$3.35M Buy
141,800
+90,800
+178% +$2.69M 1.21% 31
2019
Q2 		$1.53M Buy
+51,000
New +$1.17M 0.47% 37

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opaleye Management's RARX Position: Q1 2020 in Review

Opaleye Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2020, closing a stake of 141,800 shares — an estimated $6.66M sold.

Opaleye Management first reported a position in RARX in Q2 2019 and held it in 3 quarters. The position peaked at $6.66M in Q4 2019. 144 funds tracked by Wall St. Rank hold RARX as of Q1 2020.

  • Opaleye Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Opaleye Management sold 141,800 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $6.66M.
  • Opaleye Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Opaleye Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $6.66M in Q4 2019.
  • 144 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.